MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (MPNs). The ...
The slew of news from the JP Morgan Healthcare conference that started this morning started with a trio of takeover deals from Johnson & Johnson, Novartis, and MSD. J&J’s $2 billion play for ...
Pegasus Tel Inc. stock grades by Barron's. View PTEL fundamental and sentiment analysis powered by MarketGrader.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback